News / Blogs



   Anogen’s IL-17A monoclonal antibodies, clone 10F9 and clone 2D11, have been shown to neutralize IL-17A induced IL-6 expression in human dermal fibroblasts. The IC50 was < 0.25mg/ml.


    In a recent study with Alzheimer's disease animal model (APP/PS1 double transgenic mice), Anogen anti- amyloid peptide N-terminus antibody clone 3F5 reduced plaque on brain and improved cognition.


    More than 50 new hybridomas were developed. These hybridomas secrete monoclonal antibodies against important therapeutic targets suct as PD-1, PDL-1 and IL-17A. The monoclonal antibodies are under evaluation. An assay that measures PDL-1 concentration in blood samples has been developed.


     Developed antibodies against primary tumor cells of triple negative breast cancer.


    Participated in the laboratory medicine and pathology (LMP) vendor show in University of Toronto. 


     Developed amyloid beta 42 peptide ELISA kit.  Completed evaluation of anti-amyloid peptide antibodies with transgenic Alzheimer's disease mouse model.  


    Launched an upgraded website: www.anogen.net


    Line of Mouse ELISA Kits released.



    Started developing animal cytokine and chemokine products. New ELISA Kit products for mouse cytokine and receptors have been released.

    Set up a Facebook page and storefront.

    Released new Interleukin-6 (IL-6) anti-human antibodies and Tau Protein (Thr181 Phosphorylated) anti-human and mouse antibodies. They can be found in our monoclonal antibody listings.


    Alpha 1-Antitrypsin and Alpha-Synuclein anti-human antibodies released.

    Interleukin-13 (IL-13) ELISA kit released.

    Beta amyloid peptide N-terminal and 40 anti-human antibodies released.

    Multiplex ELISA kit for simultaneous quantitative determination of pro-inflammatory cytokines released.

    Started preparing a new facility in Orlando, FL, USA.


    Monoclonal antibodies for Interleukin-2, H.pylori(HP) cytotokine associated gene A protein (CagA) and M. tuberculosis (TB) 38Kd antigen released.

    “Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury” published in International Immunopharmacology.


    Received Certificate of Recognition from the City of Mississauga on Anogen's 20th Anniversary.

    Developed panels of monoclonal antibodies to Alzheimer’s disease.



    Introduced Beta-2 Microglobulin matched antibody pair, Beta-2 Microglobulin and p24 ELISA kits.

    Polyclonal antibodies for FPRL-1 and PML and a line of new phosphorylated monoclonal antibodies for CREB [p-S133], ELK-1 [pS383], and STAT5b [p-T694] released.


    New lung carcinoma, free PSA, CEA, AFP, NSE and CA-125 antibodies released.

    Free PSA and AFP ELISA kits released.


    Anogen introduced our new line of ELISPot kits.

    US patent “Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8” granted.


    US patent “Monoclonal Antibodies Recognizing Human Platelet Membrane Glycoproteins And Use Thereof In Anti-Thrombotic Therapy” granted.


    Anti-human platelet GPIIb/IIIa chimeric antibody completed pre-clinical studies.


    Certified ISO 13485:03 Medical Devices under the general practice of the ISO 9001 Quality System.

    Humanized monoclonal antibodies to human platelet GPIIb/IIIa, to human IL-8 and to human MCP-1 developed for therapeutics.


    Anti-IL8 neutralizing antibody cream (Abcream), developed for topical treatment of psoriasis and eczema, completed clinical trials in China.


    Received patents from Australia, Canadian, China, and EU for "Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8".


    Developed a proprietary technology for topical antibody treatment of various skin conditions, representing a new area of antibody therapy.


    Monoclonal antibodies to human serum amyloid A (SAA) and SAA ELISA Kit developed.

    Development of revolutionary anti-chemokine topical therapy for skin conditions started.



    Developed panels of monoclonal antibodies to Chemokines MCP-1 and MCP-3 and ELISA Kits.

    Received grant from National Research Council (NRC) Canada Biotechnology Contribution Program on the “Development Of A Specific & Sensitive Assay For Blood-Borne Non-A, Non-B Hepatitis Virus”.


    Developed panel of monoclonal antibodies to Chemokines Interleukin-8 (IL-8) and IL-8 ELISA kit.


    Developed panels of monoclonal antibodies to Hepatitis C and HIV viruses.


    Anogen-Yes Biotech Laboratories Ltd. was registered at Mississauga, Ontario, Canada.